Ticagrelor + Placebo

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Community Acquired Pneumonia, Severe

Conditions

Community Acquired Pneumonia, Severe

Trial Timeline

Aug 1, 2014 → Dec 1, 2015

NCT ID

NCT01998399

About Ticagrelor + Placebo

Ticagrelor + Placebo is a phase 2 stage product being developed by AstraZeneca for Community Acquired Pneumonia, Severe. The current trial status is terminated. This product is registered under clinical trial identifier NCT01998399. Target conditions include Community Acquired Pneumonia, Severe.

What happened to similar drugs?

2 of 13 similar drugs in Community Acquired Pneumonia, Severe were approved

Approved (2) Terminated (2) Active (9)

✅IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacinPfizerApproved

✅TelithromycinSanofiApproved

🔄Ceftaroline + CeftriaxonePfizerPhase 3

🔄Azithromycin microspheres 2.0 single dosePfizerPhase 3

🔄tigecyclinePfizerPhase 3

🔄Azithromycin SRPfizerPhase 3

❌Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycinPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03615924	Phase 3	Terminated	Sep 26, 2018	Aug 13, 2020	Sickle Cell Disease
NCT03354429	Phase 3	Completed	Jan 22, 2018	Dec 13, 2019	Acute Ischaemic Stroke
NCT02482298	Phase 2	Completed	Jul 9, 2015	Nov 16, 2016	Sickle Cell Disease
NCT02352402	Phase 3	UNKNOWN	Mar 1, 2015	Aug 1, 2020	Coronary Artery Disease
NCT02110303	Phase 2/3	Completed	Mar 1, 2015	Apr 1, 2018	Coronary Artery Disease
NCT02335099	Phase 1/2	Completed	Dec 1, 2014	Jun 1, 2019	End Stage Renal Disease
NCT01998399	Phase 2	Terminated	Aug 1, 2014	Dec 1, 2015	Community Acquired Pneumonia, Severe
NCT02070653	Phase 2	Completed	Mar 1, 2014	Jul 1, 2017	Abdominal Aortic Aneurysm
NCT01347580	Approved	Completed	Sep 1, 2011	Nov 1, 2013	Myocardial Infarction

Competing Products

17 competing products in Community Acquired Pneumonia, Severe

See all competitors

Product	Company	Stage	Hype Score
ONO-5046Na + ONO-5046Na	Ono Pharmaceutical	Phase 2	35
Ceftaroline + Ceftriaxone	Pfizer	Phase 3	40
Azithromycin microspheres 2.0 single dose	Pfizer	Phase 3	40
tigecycline	Pfizer	Phase 3	40
IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacin	Pfizer	Approved	43
Azithromycin SR	Pfizer	Phase 3	40
Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycin	Pfizer	Phase 3	32
Azithromycin SR + Amoxiclav	Pfizer	Pre-clinical	18
Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycin	Pfizer	Phase 3	32
tigecycline	Pfizer	Phase 3	40
Zinforo (ceftaroline fosamil)	Pfizer	Pre-clinical	26
Tigecycline + Levofloxacin	Pfizer	Phase 3	40
Azithromycin	Pfizer	Phase 3	40
Telithromycin	Sanofi	Approved	43
Omadacycline + Moxifloxacin	Zai Lab	Phase 3	41
ceftobiprole medocaril + IV standard-of-care cephalosporin	Basilea Pharmaceutica	Phase 3	34
EDP-420 / Duration of Treatment - 3 days + Telithromycin / Duration of Treatment - 7 days	Enanta Pharmaceuticals	Phase 2	21